4/30/2013 8:12:11 AM
Staying up-to-date has never been simpler. Sign up for the free
GenePool newsletter today!
Regeneron Pharmaceuticals Inc.'s (REGN) stock price tripled last year, and the compensation of co-founder and Chief Executive Leonard Schleifer nearly did, too. Mr. Schleifer made $30.04 million in 2012, according to filings with the Securities and Exchange Commission, up from $10.56 million the previous year. Fellow co-founder and Chief Scientific Officer George Yancopoulos earned even more, raking in $81.55 million, an eight-fold increase. However, the executives won't see much of that compensation right away, as the vast majority of it came in the form of stock options and awards, which will take four to five years to vest. Regeneron's board of directors said the increases were warranted after a string of commercial, regulatory and stock-market successes last year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by